| COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature A Murt, AE Eskazan, U Yılmaz, T Ozkan, MC Ar Journal of medical virology 93 (1), 43, 2021 | 69 | 2021 |
| Dasatinib‐induced pulmonary arterial hypertension N Özgür Yurttaş, AE Eşkazan British Journal of Clinical Pharmacology 84 (5), 835-845, 2018 | 62 | 2018 |
| Bone marrow transplantation for Behçet’s disease: a case report and systematic review of the literature T Soysal, A Salihoğlu, SN Esatoğlu, E Gültürk, AE Eşkazan, G Hatemi, ... Rheumatology 53 (6), 1136-1141, 2014 | 60 | 2014 |
| Diyarbakır Eğitim Araştırma Hastanesi sağlık çalışanlarında kesici delici alet yaralanmalarının değerlendirilmesi Ş Kaya, B Baysal, AE Eşkazan, H Çolak Viral Hepatit Dergisi 18 (3), 107-10, 2012 | 49 | 2012 |
| Novel therapeutic approaches in chronic myeloid leukemia NÖ Yurttaş, AE Eşkazan Leukemia Research 91, 106337, 2020 | 46 | 2020 |
| Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities Z Narlı Özdemir, NA Kılıçaslan, M Yılmaz, AE Eşkazan International journal of hematology 117 (1), 3-15, 2023 | 31 | 2023 |
| Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. F Sahin, G Saydam, M Cömert, B Uz, AS Yavuz, E Turan, İ Yönal, H Atay, ... Turkish Journal of Haematology: Official Journal of Turkish Society of …, 2013 | 30 | 2013 |
| Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs A Erçalışkan, D Seyhan Erdoğan, AE Eşkazan Blood advances 5 (17), 3344-3353, 2021 | 21 | 2021 |
| The changing epidemiology of bloodstream infections and resistance in hematopoietic stem cell transplantation recipients M Yemişen, İİ Balkan, A Salihoğlu, AE Eşkazan, B Mete, MC Ar, ... Turkish Journal of Hematology 33 (3), 216, 2016 | 21 | 2016 |
| Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia S Malik, S Hassan, AE Eşkazan Expert Review of Hematology 14 (11), 975-978, 2021 | 17 | 2021 |
| COVID-19 in chronic-phase chronic myeloid leukemia patients: a single-center survey from Turkey U Yılmaz, A Pekmezci, Y Gül, AE Eşkazan Turkish Journal of Hematology 38 (1), 79, 2021 | 15 | 2021 |
| Tocilizumab in COVID-19: the Cerrahpaşa-PREDICT score AE Eşkazan, İİ Balkan, KC Demirbaş, MC Ar, R Karaali, Y Sekibağ, ... Journal of Infection and Chemotherapy 27 (9), 1329-1335, 2021 | 13 | 2021 |
| Evolving treatment strategies in CML–moving from early and deep molecular responses to TKI discontinuation and treatment‐free remission: is there a need for longer‐term trial … AE Eşkazan British journal of clinical pharmacology 84 (8), 1635, 2018 | 13 | 2018 |
| Gilteritinib in the management of acute myeloid leukemia: current evidence and future directions EN Kantarcı, AE Eşkazan Leukemia Research 114, 106808, 2022 | 12 | 2022 |
| Vincristine as an adjunct to therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a single-institution experience S Öngören, A Salihoğlu, T Apaydın, S Sadri, AE Eşkazan, MC Ar, ... Balkan Medical Journal 35 (6), 417, 2018 | 12 | 2018 |
| Treatment of patients with immune thrombocytopenia admitted to the emergency room I Bavunoğlu, AE Eşkazan, MC Ar, M Cengiz, S Yavuzer, A Salihoğlu, ... International journal of hematology 104, 216-222, 2016 | 12 | 2016 |
| Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis E Öztürk, M Özbalak, S Berk, I Erdoğan, E Avşar, A Dolgun, M Çetiner, ... Leukemia & lymphoma 57 (5), 1211-1214, 2016 | 12 | 2016 |
| Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest? AE Eşkazan British Journal of Clinical Pharmacology 85 (10), 2241, 2019 | 11 | 2019 |
| Retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience Ş Öngören, AE Eşkazan, S Berk, T Elverdi, A Salihoğlu, MC Ar, Z Başlar, ... Turkish Journal of Hematology 34 (4), 291, 2017 | 11 | 2017 |
| Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? T Elverdi, MD Özer Çerme, T Aydın, AE Eşkazan Expert Review of Clinical Pharmacology 14 (10), 1183-1188, 2021 | 10 | 2021 |